The Engagement of Cittadinanzattiva-Active Citizenship Network on Therapeutic Adherence

At the National level
The topic of therapeutic adherence was addressed by Cittadinanzattiva through the National Coalition of Associations for Patients Suffering Chronic Diseases (CnAMC). The CnAMC is a network of Cittadinanzattiva established in 1996, which represents an example of crosscutting alliance between associations of people with chronic and rare diseases for the protection of their rights. It has about one hundred members.

 

At the EU level
In line with our commitment at the national level, Active Citizenship Network has been addressing the topic also at the European level with the following initiatives:

  • (2017-ongoing): The support of Active Citizenship Network on value added medicines.
  • 2018: “Therapeutic adherence: value the impact for patients and healthcare system” was the title of the 12th European Patients’ Rights Day, celebrated last May 23rd by Active Citizenship Network at the European Parliament. The event was an occasion to foster communication among different partners/actors in the healing and caring process to improve adherence to treatments and take commitments. Starting from concrete experiences, the conference provided patient associations, health care professionals, scientists, pharmacists, industry and representatives of national and European institutions with the opportunity to work together in identifying the main changes that are necessary to fight non-adherence to treatment plans.
  • 2018-2019: As follow up of the 12th European Patients’ Rights Day, ACN launched a communication campaign called “From Therapeutic Adherence to Therapeutic Alliance”. The campaign involved a video recorded in English which was disseminated at the EU level as well as several videos recorded in national languages and spread in Bulgaria, Cyprus, Turkey Cyprus, Ireland, Greece, Hungary, Italy, Malta, Spain with the direct involvement of ACN’s national partners.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.